{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:58:23Z","timestamp":1785495503434,"version":"3.56.0"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>MOGAD is a rare autoimmune encephalomyelitis that shares similar clinical manifestations with other central nervous system demyelinating diseases. However, they must be distinguished due to their distinct pathogenesis and treatment methods. Currently, the clinical diagnosis of MOGAD primarily relies on patients\u2019 clinical manifestations and imaging features, with biomarker application being relatively limited. Meanwhile, research on MOGAD biomarkers has advanced rapidly, with findings mainly focusing on imaging features, antibody titers, nerve cell markers, cytokines, and inflammatory cell ratios. These biomarkers can distinguish among various autoimmune with similar clinical manifestations and exhibit certain specificity. If these biomarker findings are applied to the clinical diagnosis of MOGAD, they could enhance diagnostic accuracy and support earlier and more accurate diagnosis, while providing a scientific basis for evaluating disease progression and prognosis. We discuss the biomarkers and emerging biomarkers of MOGAD, emphasizing the specific changes and aspects that may be applicable to clinical diagnosis and treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1807565","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:04:18Z","timestamp":1785492258000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers for myelin oligodendrocyte glycoprotein-associated disease: recent advances and future"],"prefix":"10.3389","volume":"17","author":[{"given":"Qingying","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Neurology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzi","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxin","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruogu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"Department of Neurology, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.20.24061","article-title":"MOGAD: how it differs from and resembles other neuroinflammatory disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1137998","article-title":"Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease","volume":"14","author":"Corbali","year":"2023","journal-title":"Front Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100913","article-title":"Humoral signatures of MOG-antibody-associated disease track with age and disease activity","volume":"4","author":"Spatola","year":"2023","journal-title":"Cell Rep Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/wco.0000000000000813","article-title":"Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases","volume":"33","author":"Mader","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13102344","article-title":"MOGAD: a shifting landscape-from pathogenesis to personalised management, global perspectives and Latin American insights","volume":"13","author":"Ciampi","year":"2025","journal-title":"Biomedicines"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.4251","article-title":"Autoimmune encephalitis misdiagnosis in adults","volume":"80","author":"Flanagan","year":"2023","journal-title":"JAMA Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000883","article-title":"Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France","volume":"7","author":"H\u00e9bert","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330074","article-title":"MOG antibody-associated encephalitis in adult: clinical phenotypes and outcomes","volume":"94","author":"Lee","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2743","article-title":"Application of 2015 seronegative neuromyelitis optica spectrum disorder diagnostic criteria for patients with myelin oligodendrocyte glycoprotein IgG-associated disorders","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11737-8","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges","volume":"270","author":"Al-Ani","year":"2023","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000012467","article-title":"Comparison of MRI lesion evolution in different central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11910-025-01432-8","article-title":"Uncommon non-MS demyelinating disorders of the central nervous system","volume":"25","author":"Mukherjee","year":"2025","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","article-title":"Clinical course of multiple sclerosis","volume":"8","author":"Klineova","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51404","article-title":"Mortality of neuromyelitis optica spectrum disorders in a Chinese population","volume":"8","author":"Du","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD","volume":"95","author":"Duchow","year":"2024","journal-title":"Ann Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334764","article-title":"Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD","volume":"96","author":"H\u00e4u\u00dfler","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders","volume":"84","author":"Jacob","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211018987","article-title":"Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis","volume":"28","author":"Messina","year":"2022","journal-title":"Mult Scler"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-ABN.33","article-title":"Spinal cord involvement in MOGAD, AQP4-Ab NMOSD & MS","volume":"93","author":"Mariano","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28871","article-title":"Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes","volume":"4","author":"Fadda","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16284","article-title":"Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: a systematic review and meta-analysis","volume":"31","author":"Hagbohm","year":"2024","journal-title":"Eur J Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000012599","article-title":"CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies","volume":"97","author":"Zhao-Fleming","year":"2021","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420515","article-title":"Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology","volume":"42","author":"Br\u00fcck","year":"1997","journal-title":"Ann Neurol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25411","article-title":"Brain and cord imaging features in neuromyelitis optica spectrum disorders","volume":"85","author":"Cacciaguerra","year":"2019","journal-title":"Ann Neurol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae138","article-title":"Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases","volume":"147","author":"Sun","year":"2024","journal-title":"Brain"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324826","article-title":"Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS","volume":"92","author":"Duan","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26951","article-title":"Grey matter atrophy and its relationship with white matter lesions in patients with myelin oligodendrocyte glycoprotein antibody-associated disease, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, and multiple sclerosis","volume":"96","author":"Cortese","year":"2024","journal-title":"Ann Neurol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331137","article-title":"Cerebral enhancement in MOG antibody-associated disease","volume":"95","author":"Elsbernd","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.102939","article-title":"Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: a systematic review and meta-analysis","volume":"33","author":"Ineichen","year":"2022","journal-title":"NeuroImage Clin"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211034362","article-title":"Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: a three-dimensional fluid-attenuated inversion recovery MRI study","volume":"28","author":"Tzanetakos","year":"2022","journal-title":"Mult Scler"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000206820","article-title":"Tumefactive demyelination in MOG Ab-associated disease, multiple sclerosis, and AQP-4-IgG-positive neuromyelitis optica spectrum disorder","volume":"100","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01005-2","article-title":"The influence of MOGAD on diagnosis of multiple sclerosis using MRI","volume":"20","author":"Geraldes","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0001","article-title":"Unilateral leptomeningeal enhancement in myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease","volume":"77","author":"Budhram","year":"2020","journal-title":"JAMA Neurol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200183","article-title":"Timing of MOG-IgG testing is key to 2023 MOGAD diagnostic criteria","volume":"11","author":"Forcadela","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10024-0","article-title":"Cell-based assays for the detection of MOG antibodies: a comparative study","volume":"267","author":"Gastaldi","year":"2020","journal-title":"J Neurol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231172954","article-title":"Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes","volume":"29","author":"Reindl","year":"2023","journal-title":"Mult Scler"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad122","article-title":"Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids","volume":"146","author":"Matsumoto","year":"2023","journal-title":"Brain"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000201662","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflamm"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001095","article-title":"Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability","volume":"9","author":"Kwon","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B69","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ana.26931","article-title":"Diagnostic utility of MOG antibody testing in cerebrospinal fluid","volume":"96","author":"Redenbaugh","year":"2024","journal-title":"Ann Neurol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221093789","article-title":"Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria","volume":"28","author":"Fadda","year":"2022","journal-title":"Mult Scler"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1380541","article-title":"Myelin oligodendrocyte glycoprotein antibody titers by fixed cell-based assay: positive predictive value and impact of sample collection timing","volume":"15","author":"Budhram","year":"2024","journal-title":"Front Neurol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251313744","article-title":"Testing for myelin oligodendrocyte glycoprotein antibodies: who, what, where, when, why, and how","volume":"31","author":"Budhram","year":"2025","journal-title":"Mult Scler"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330237","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study","volume":"94","author":"Gastaldi","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-337039","article-title":"Biomarkers to predict relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis","volume":"97","author":"Andersen","year":"2026","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105130","article-title":"Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"81","author":"Martin","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018309","article-title":"Neurofilaments and neurofilament proteins in health and disease","volume":"9","author":"Yuan","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115382","article-title":"Secreted neurofilament light chain after neuronal damage induces myeloid cell activation and neuroinflammation","volume":"44","author":"Kahn","year":"2025","journal-title":"Cell Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.016","article-title":"Mechanisms underlying inflammation in neurodegeneration","volume":"140","author":"Glass","year":"2010","journal-title":"Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15549","article-title":"Serum neurofilament light chain in adult and pediatric patients with myelin oligodendrocyte glycoprotein antibody-associated disease: correlation with relapses and seizures","volume":"160","author":"Luo","year":"2022","journal-title":"J Neurochem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200347","article-title":"Neurofilament light chain as a discriminator of disease activity status in MOG antibody-associated disease","volume":"12","author":"Gomes","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200404","article-title":"Extracellular vesicle marker changes associated with disease activity in relapsing-remitting multiple sclerosis","volume":"12","author":"Lim Falk","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200188","article-title":"Serum biomarker profiles discriminate AQP4 seropositive and double seronegative neuromyelitis optica spectrum disorder","volume":"11","author":"Carta","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1388734","article-title":"Serum NfL and EGFR\/NfL ratio mRNAs as biomarkers for phenotype and disease severity of myelin oligodendrocyte glycoprotein IgG-associated disease","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12135-w","article-title":"Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort","volume":"271","author":"Arroyo Pereiro","year":"2024","journal-title":"J Neurol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102057","article-title":"Seizure occurrence in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis","volume":"42","author":"Shen","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105729","article-title":"Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: a descriptive cohort study","volume":"88","author":"Schindler","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad063","article-title":"Early blood neurofilament light chain and myelin oligodendrocyte glycoprotein antibody levels associate with different disease courses of myelin oligodendrocyte glycoprotein-associated disease in children","volume":"5","author":"Horellou","year":"2023","journal-title":"Brain Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211063756","article-title":"Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: longitudinal assessment of serum neurofilament light chain","volume":"28","author":"Hyun","year":"2022","journal-title":"Mult Scler"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320287","article-title":"Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders","volume":"90","author":"Mariotto","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082408","article-title":"Tau in oligodendrocytes takes neurons in sickness and in health","volume":"19","author":"LoPresti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2008.03.002","article-title":"Microtubule-associated protein tau in development, degeneration and protection of neurons","volume":"85","author":"Wang","year":"2008","journal-title":"Prog Neurobiol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/nen.0000000000000030","article-title":"Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression","volume":"73","author":"Ferrer","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102594","article-title":"Unknown roles of tau pathology in neurological disorders. Challenges and new perspectives","volume":"103","author":"Olesen","year":"2025","journal-title":"Ageing Res Rev"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00256-3","article-title":"Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study","volume":"21","author":"Korley","year":"2022","journal-title":"Lancet Neurol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13898","article-title":"Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI","volume":"20","author":"Shahim","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2011.01.005","article-title":"Gfap in health and disease","volume":"93","author":"Middeldorp","year":"2011","journal-title":"Prog Neurobiol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12974-022-02600-0","article-title":"Impaired response of blood neutrophils to cell-death stimulus differentiates aqp4-igg-seropositive nmosd from mogad","volume":"19","author":"Schroeder-Castagno","year":"2022","journal-title":"J Neuroinflamm"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-317969","article-title":"Csf cytokine profile in mog-igg+ neurological disease is similar to aqp4-igg+ nmosd but distinct from ms: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200150","article-title":"Dramatic response to anti-il-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease","volume":"10","author":"McLendon","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241254731","article-title":"Contributions of csf interleukin-6 elevation to the pathogenesis of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"30","author":"Uzawa","year":"2024","journal-title":"Mult Scler"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/s41467-020-16625-7","article-title":"Transcriptomics and proteomics reveal a cooperation between interferon and t-helper 17 cells in neuromyelitis optica","volume":"11","author":"Agasing","year":"2020","journal-title":"Nat Commun"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000311","article-title":"Effects of neuromyelitis optica-igg at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864133","article-title":"Kappa free light chains, soluble interleukin-2 receptor, and interleukin-6 help explore patients presenting with brain white matter hyperintensities","volume":"13","author":"Levraut","year":"2022","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000000317","article-title":"Efficacy of the anti-il-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102483","article-title":"Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and mog-antibody-associated diseases: a case-series","volume":"46","author":"Rigal","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000007312","article-title":"Tocilizumab treatment in severe recurrent anti-mog-associated optic neuritis","volume":"92","author":"Hayward-Koennecke","year":"2019","journal-title":"Neurology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (mog) antibodies. part 1: results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory mog-igg-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200362","article-title":"Profile and usefulness of serum cytokines to predict prognosis in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"12","author":"Villacieros-\u00c1lvarez","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B115","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12883-025-04145-0","article-title":"Intrathecal interleukin-6 levels are associated with progressive disease and clinical severity in multiple sclerosis","volume":"25","author":"Itorralba","year":"2025","journal-title":"BMC Neurol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cell.2018.11.035","article-title":"Recirculating intestinal iga-producing cells regulate neuroinflammation via il-10","volume":"176","author":"Rojas","year":"2019","journal-title":"Cell"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.01.009","article-title":"Seeking balance: potentiation and inhibition of multiple sclerosis autoimmune responses by il-6 and il-10","volume":"73","author":"Ireland","year":"2015","journal-title":"Cytokine"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578351","article-title":"A protective effect of lower mhc-ii expression in mogad","volume":"391","author":"Rechtman","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2013.10.016","article-title":"Essential role of il-10\/stat3 in chronic stress-induced immune suppression","volume":"36","author":"Hu","year":"2014","journal-title":"Brain Behav Immun"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577361","article-title":"Serum level of il-1\u03b2 in patients with inflammatory demyelinating disease: marked upregulation in the early acute phase of mog antibody associated disease (mogad)","volume":"348","author":"Kwon","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.013","article-title":"Il-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments","volume":"25","author":"Luchtman","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200146","article-title":"Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum","volume":"14","author":"Berek","year":"2023","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01026","article-title":"Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: a systematic review and meta-analysis of 226 studies with 13,526 multiple sclerosis patients","volume":"13","author":"Bai","year":"2019","journal-title":"Front Neurosci"},{"key":"B124","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41419-019-1716-9","article-title":"Microglia-derived tnf-\u03b1 mediates endothelial necroptosis aggravating blood brain-barrier disruption after ischemic stroke","volume":"10","author":"Chen","year":"2019","journal-title":"Cell Death Dis"},{"key":"B125","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1038\/s41467-022-34412-4","article-title":"Reactive astrocytes transduce inflammation in a blood-brain barrier model through a tnf-stat3 signaling axis and secretion of alpha 1-antichymotrypsin","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.109898","article-title":"Th17 cell promotes apoptosis of il-23r(+) neurons in experimental autoimmune encephalomyelitis","volume":"259","author":"Sonar","year":"2024","journal-title":"Clin Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2174\/187152711794653751","article-title":"Targeting tnf-\u03b1 to elucidate and ameliorate neuroinflammation in neurodegenerative diseases","volume":"10","author":"Frankola","year":"2011","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1172\/jci164637","article-title":"Ipsc-derived reactive astrocytes from patients with multiple sclerosis protect cocultured neurons in inflammatory conditions","volume":"133","author":"Kerkering","year":"2023","journal-title":"J Clin Invest"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51964","article-title":"Association of plasma spd-1 and spd-l1 with disease status and future relapse in aqp4-igg (+) nmosd","volume":"11","author":"Liu","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810235","article-title":"Tnf-\u03b1 and il-1\u03b2 modulate blood-brain barrier permeability and decrease amyloid-\u03b2 peptide efflux in a human blood-brain barrier model","volume":"23","author":"Versele","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1187824","article-title":"A retrospective study of myelin oligodendrocyte glycoprotein antibody-associated disease from a clinical laboratory perspective","volume":"14","author":"Wang","year":"2023","journal-title":"Front Neurol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083606","article-title":"Cd4-positive t-cell responses to mog peptides in mog antibody-associated disease","volume":"26","author":"Ono","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1999-0","article-title":"Mafg-driven astrocytes promote cns inflammation","volume":"578","author":"Wheeler","year":"2020","journal-title":"Nature"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded b cells in multiple sclerosis bind ebv ebna1 and glialcam","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-019-0369-4","article-title":"Aberrant oligodendroglial-vascular interactions disrupt the blood-brain barrier, triggering cns inflammation","volume":"22","author":"Niu","year":"2019","journal-title":"Nat Neurosci"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2014.11.013","article-title":"Role of the blood-brain barrier in multiple sclerosis","volume":"45","author":"Ortiz","year":"2014","journal-title":"Arch Med Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12883-016-0622-3","article-title":"Increased plasma levels of epithelial neutrophil-activating peptide 78\/cxcl5 during the remission of neuromyelitis optica","volume":"16","author":"Yang","year":"2016","journal-title":"BMC Neurol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515586084","article-title":"Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica","volume":"22","author":"Hertwig","year":"2016","journal-title":"Mult Scler"},{"key":"B139","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"Mog-igg in nmo and related disorders: a multicenter study of 50 patients. part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1293100","article-title":"Systemic inflammation response index is a useful indicator in distinguishing mogad from aqp4-igg-positive nmosd","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2306572120","article-title":"T cell deletional tolerance restricts aqp4 but not mog cns autoimmunity","volume":"120","author":"Sagan","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann Neurol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-321988","article-title":"Peripheral blood helper t cell profiles and their clinical relevance in mog-igg-associated and aqp4-igg-associated disorders and ms","volume":"91","author":"Liu","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.679770","article-title":"Regulatory t cells increase after rh-mog stimulation in non-relapsing but decrease in relapsing mog antibody-associated disease at onset in children","volume":"12","author":"Horellou","year":"2021","journal-title":"Front Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/brain\/awh453","article-title":"Intrathecal activation of the il-17\/il-8 axis in opticospinal multiple sclerosis","volume":"128","author":"Ishizu","year":"2005","journal-title":"Brain"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149411","article-title":"B cell, th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in mog antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PloS One"},{"key":"B147","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12974-015-0351-3","article-title":"Stat4 controls gm-csf production by both th1 and th17 cells during eae","volume":"12","author":"McWilliams","year":"2015","journal-title":"J Neuroinflamm"},{"key":"B148","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan micrornas","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.948959","article-title":"Micrornas in extracellular vesicles: sorting mechanisms, diagnostic value, isolation, and detection technology","volume":"10","author":"Xu","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"12280","DOI":"10.1007\/s12035-025-04932-3","article-title":"Serum sev mirnas as biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"62","author":"Kim","year":"2025","journal-title":"Mol Neurobiol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-021-02893-4","article-title":"miR-20a suppresses Treg differentiation by targeting Map3k9 in experimental autoimmune encephalomyelitis","volume":"19","author":"Wang","year":"2021","journal-title":"J\u00a0Transl Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-68","article-title":"Exosomes as mediators of neuroinflammation","volume":"11","author":"Gupta","year":"2014","journal-title":"J\u00a0Neuroinflamm"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2013.0516","article-title":"Extracellular vesicles as modulators of cell-to-cell communication in the healthy and diseased brain","volume":"369","author":"Pegtel","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109761","article-title":"Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS\/MS and Simoa","volume":"116","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s40001-022-00814-9","article-title":"IL-6 and TNF-\u03b1 responses to acute and regular exercise in adult individuals with multiple sclerosis (MS): a systematic review and meta-analysis","volume":"27","author":"Shobeiri","year":"2022","journal-title":"Eur J Med Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:04:20Z","timestamp":1785492260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":155,"alternative-id":["10.3389\/fimmu.2026.1807565"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1807565","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1807565"}}